- $88.09m
- $74.94m
- $0.54m
Brief: Mainz Biomed Establishes Strategic Partnership With TomaLab To Expand Availability Of ColoAlert In Italy
Brief: Mainz Biomed NV- Reconaasense Designed To Evaluate Gold Standard At-Home Colorectal Cancer Screening Test, On Track To Commence Enrollment In Mid-2024
Brief: Mainz Biomed Reports Positive Topline Results From U.S. Eaarly Detect Study Evaluating Novel MRNA Biomarkers
U.S. RESEARCH ROUNDUP-Clorox, GoDaddy, Reynolds Consumer Products
Brief: Mainz Biomed Partners with Liquid Biosciences to Develop Colorectal Screening Test
Brief: Mainz Biomed Presents Results Of Colofuture Study
Brief: Mainz Biomed: Presents Groundbreaking Results Of Colofuture Study
Brief: Mainz Biomed Secures Up To $50 Mln In New Funding
Brief: Mainz Biomed Expands Into Romania Through Partnership With Bioclinica
Brief: Mainz Biomed Announces Partnership With The Instituto De Microecologia To Expand Coloalert® Commercialization In Spain And Portugal
Brief: Mainz Biomed Announces Partnership With Labor Staber To Expand Coloalert Commercialization In Germany
Brief: Mainz Biomed NV Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Mainz Biomed Announces U.S. Extension Of Colofuture Study To Evaluate Integration Of Novel MRNA Biomarkers Into Coloalert
Brief: Mainz Biomed Provides Third Quarter 2022 Update
Brief: Mainz Biomed Strengthens Board Of Directors With Nomination Of Heiner Dreismann And Gregory Tibbitts
U.S. STOCKS ON THE MOVE-Corning, Stride, Gatos Silver
U.S. STOCKS ON THE MOVE-Corning, F5 Inc, Cortexyme
U.S. STOCKS ON THE MOVE-JinkoSolar, Gatos Silver, Vaccinex Inc
U.S. STOCKS ON THE MOVE-JinkoSolar, Tyme Technologies, Texas Instruments